Sobi North America presented data at the ACR Convergence 2025 meeting showcasing the positive impact of their immunology portfolio on rare inflammatory conditions. The data included promising results from studies on Nanoecapsulated Sirolimus plus Pegadricase (NASP), Vonjo® (pacritinib), and Gamifant® (emapalumab-lzsg). Specifically, NASP showed significant reductions in serum uric acid levels, gout flares, joint pain, and improvements in quality of life measures. The FDA has set a target action date of June 27, 2026, for NASP’s BLA submission. Additionally, Gamifant was approved as the first-ever treatment for adults and children with Macrophage Activation Syndrome in Still’s disease in June 2025.
In the DISSOLVE Trials, NASP demonstrated a rapid reduction in serum uric acid levels and a significant decrease in gout flares compared to placebo. Patients receiving NASP also experienced improvements in joint pain and quality of life measures. The data showed that NASP has the potential to optimize the treatment of uncontrolled gout by reducing disease burden. Additionally, tophus outcomes from the Phase III studies indicated a substantial reduction in tophi size in patients treated with NASP.
Data on Gamifant in patients with Macrophage Activation Syndrome in Still’s disease highlighted positive outcomes in terms of complete response rates and normalization of laboratory parameters. The most common adverse reactions for Gamifant included viral infections, rash, anemia, and infusion-related reactions. The FDA’s approval of Gamifant in June 2025 marked a significant advancement in the treatment of this condition. In a post hoc analysis, Gamifant showed efficacy in treating Macrophage Activation Syndrome (MAS) secondary to Still’s Disease, with consistent response rates and similar glucocorticoid doses tapering across different MAS presentations. Baseline pharmacodynamic markers showed reductions in CXCL9 and ferritin with Gamifant treatment. A study on Vonjo (pacritinib) and VEXAS Syndrome was presented, highlighting the first randomized trial for this complex condition. Consensus criteria were developed to define VEXAS Flare, aiding in research and patient care. A Disease Activity Index (DAI) was created to measure active inflammation in VEXAS syndrome patients, with ongoing validation efforts. Two patients experienced fatal adverse reactions, including multiple organ dysfunction and circulatory shock. The most common adverse reactions for Gamifant included viral infection, rash, anemia, leukopenia, thrombosis, bacterial infections, headache, and more. VONJO is a kinase inhibitor for adults with myelofibrosis. Adverse reactions may include hemorrhage, diarrhea, thrombocytopenia, and prolonged QT interval. NASP is an investigational medicine for uncontrolled gout. Gamifant is an approved anti-interferon gamma monoclonal antibody, while Vonjo is indicated for myelofibrosis. VEXAS syndrome is caused by mutations in the UBA1 gene. Sobi is a biopharma company focused on rare diseases. 1. The stock market reached record highs today, with the S&P 500 closing at 4,300 points and the Dow Jones Industrial Average at 34,500 points. Experts attribute the surge to positive economic data, including a decrease in unemployment rates and strong corporate earnings reports.
2. A new study published in the Journal of Medicine found that the Pfizer-BioNTech COVID-19 vaccine is 90% effective in preventing hospitalization from the Delta variant. The study analyzed data from over 10,000 patients across 15 countries, providing further evidence of the vaccine’s effectiveness against the highly contagious variant.
3. In a groundbreaking discovery, scientists have identified a new species of dinosaur in Argentina. The newly named Bajadasaurus pronuspinax is a herbivorous dinosaur with a unique neck structure featuring large, sharp spines. Researchers believe this finding will shed new light on the evolution and diversity of dinosaurs during the Late Cretaceous period.
Read more at 1. “Tesla reports record quarterly earnings, beating expectations.” – CNBC
2. “Amazon announces plans to hire 75,000 new workers.” – Wall Street Journal
3. “Apple unveils new iPhone with improved camera and battery life.” – Reuters
4. “Facebook faces antitrust lawsuit from FTC.” – Barchart
5. “Netflix surpasses 200 million subscribers worldwide.” – CBS MarketWatch: Data presented at ACR Convergence 2025 highlight Sobi’s